Find Iotalamic Acid manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Related ProductsRelated Products

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

FINISHED DOSAGE FORMULATIONS

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

JP

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Iothalamic acid, 2276-90-6, 3-acetamido-2,4,6-triiodo-5-(methylcarbamoyl)benzoic acid, 5-acetamido-2,4,6-triiodo-n-methylisophthalamic acid, Iotalamic acid [inn], Mi-216
Molecular Formula
C11H9I3N2O4
Molecular Weight
613.91  g/mol
InChI Key
UXIGWFXRQKWHHA-UHFFFAOYSA-N
FDA UNII
16CHD79MIX

Iotalamic Acid
A contrast medium in diagnostic radiology with properties similar to those of diatrizoic acid. It is used primarily as its sodium and meglumine (IOTHALAMATE MEGLUMINE) salts.
Iothalamic acid is a Radiographic Contrast Agent. The mechanism of action of iothalamic acid is as a X-Ray Contrast Activity.
1 2D Structure

Iotalamic Acid

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
3-acetamido-2,4,6-triiodo-5-(methylcarbamoyl)benzoic acid
2.1.2 InChI
InChI=1S/C11H9I3N2O4/c1-3(17)16-9-7(13)4(10(18)15-2)6(12)5(8(9)14)11(19)20/h1-2H3,(H,15,18)(H,16,17)(H,19,20)
2.1.3 InChI Key
UXIGWFXRQKWHHA-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC(=O)NC1=C(C(=C(C(=C1I)C(=O)O)I)C(=O)NC)I
2.2 Other Identifiers
2.2.1 UNII
16CHD79MIX
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Acid, Iotalamic

2. Acid, Iothalamic

3. Acid, Methalamic

4. Angio Conray

5. Angio-conray

6. Angioconray

7. Conray 420

8. Iodothalamate

9. Iothalamate

10. Iothalamate, Sodium

11. Iothalamic Acid

12. Iothalamic Acid, Calcium (2:1) Salt

13. Iothalamic Acid, Monosilver (1+) Salt

14. Iothalamic Acid, Monosodium Salt

15. Iothalamic Acid, Monosodium Salt, Dimer

16. Lopamidol

17. Methalamic Acid

18. Sodium Iothalamate

2.3.2 Depositor-Supplied Synonyms

1. Iothalamic Acid

2. 2276-90-6

3. 3-acetamido-2,4,6-triiodo-5-(methylcarbamoyl)benzoic Acid

4. 5-acetamido-2,4,6-triiodo-n-methylisophthalamic Acid

5. Iotalamic Acid [inn]

6. Mi-216

7. Nsc-759891

8. 16chd79mix

9. 3-(acetylamino)-2,4,6-triiodo-5-[(methylamino)carbonyl]benzoic Acid

10. Acidum Jotalamicum

11. Acido Iotalamico

12. Iothalamic Acid [usan]

13. Acide Iotalamique

14. Acidum Iotalamicum

15. Acide Iotalamique [inn-french]

16. Acido Iotalamico [inn-spanish]

17. Acidum Iotalamicum [inn-latin]

18. Einecs 218-897-4

19. Mi 216

20. Unii-16chd79mix

21. Iothalamic Acid [usan:usp]

22. Iothalamic-acid-d3

23. Benzoic Acid, 3-(acetylamino)-2,4,6-triiodo-5-((methylamino)carbonyl)-

24. Iothalamic Acid (usp)

25. Ec 218-897-4

26. Iothalamate [vandf]

27. Schembl38419

28. Iotalamic Acid [jan]

29. Iothalamic Acid [mi]

30. Iotalamic Acid (jp17/inn)

31. Iothalamicacid(200mg)

32. Iotalamic Acid [mart.]

33. Chembl1201300

34. Dtxsid5023164

35. Iotalamic Acid [who-dd]

36. Schembl23630220

37. Chebi:31713

38. Iothalamic Acid [usp-rs]

39. Hms3264d13

40. Pharmakon1600-01503836

41. Bcp13316

42. Hy-b1053

43. Zinc3830961

44. Iotalamic Acid [ep Impurity]

45. Nsc759891

46. Akos025402283

47. Benzoic Acid,3-(acetylamino)-2,4,6-triiodo-5-[(methylamino)carbonyl]-

48. Ac-7611

49. Ccg-213208

50. Cs-4575

51. Db09133

52. Iothalamic Acid [usp Monograph]

53. Nsc 759891

54. Ncgc00183042-01

55. Ft-0740526

56. D01258

57. Ab01563288_01

58. 276i906

59. Sr-01000944232

60. Q-201246

61. Q6064129

62. Sr-01000944232-1

63. 5-acetylamino-2,4,6-triiodo-n-methyl-isophthalamic Acid

64. 1-deoxy-1-(methylamino)-d-glucitol 5-acetamido-2,4,6 Triiodo-n-methylisophthalamate

65. Benzoic Acid, 3-(acetylamino)-2,4,6-triiodo-5-((methylamino)carbonyl

2.4 Create Date
2005-03-25
3 Chemical and Physical Properties
Molecular Weight 613.91 g/mol
Molecular Formula C11H9I3N2O4
XLogP31.9
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count4
Rotatable Bond Count3
Exact Mass613.7696 g/mol
Monoisotopic Mass613.7696 g/mol
Topological Polar Surface Area95.5 Ų
Heavy Atom Count20
Formal Charge0
Complexity421
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Conray is indicated for use in excretory urography, cerebral angiography, peripheral arteriography, venography, arthrography, direct cholangiography, endoscopic retrograde cholangiopancreatography, contrast enhancement of computed tomographic brain images, cranial computerized angiotomography, intravenous digital subtraction angiography and arterial digital subtraction angiography. Conray may also be used for enhancement of computed tomographic scans performed for detection and evaluation of lesions in the liver, pancreas, kidneys, abdominal aorta, mediastinum, abdominal cavity and retroperitoneal space.


5 Pharmacology and Biochemistry
5.1 MeSH Pharmacological Classification

Contrast Media

Substances used to allow enhanced visualization of tissues. (See all compounds classified as Contrast Media.)


5.2 FDA Pharmacological Classification
5.2.1 Active Moiety
IOTHALAMIC ACID
5.2.2 FDA UNII
16CHD79MIX
5.2.3 Pharmacological Classes
Mechanisms of Action [MoA] - X-Ray Contrast Activity
5.3 ATC Code

V - Various

V08 - Contrast media

V08A - X-ray contrast media, iodinated

V08AA - Watersoluble, nephrotropic, high osmolar x-ray contrast media

V08AA04 - Iotalamic acid


5.4 Absorption, Distribution and Excretion

Absorption

Renal accumulation is sufficiently rapid that maximum radiographic density in the calyces and pelves occurs, in most instances, about 3 to 8 minutes after injection. In patients with impaired renal function, diagnostic opacification frequently is achieved only after prolonged periods.


Route of Elimination

Following intravascular injection, Conray is rapidly transported through the circulatory system to the kidneys and is excreted unchanged in the urine by glomerular filtration. The liver and small intestine provide the major alternate route of excretion. In patients with severe renal impairment, the excretion of this contrast medium through the gallbladder and into the small intestine sharply increases.


5.5 Biological Half-Life

In patients with normal renal function, the alpha and beta half-lives of Conray were approximately 10 and 90 minutes, respectively.


REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty